TY - JOUR
T1 - Unrelated donor bone marrow transplantation for 100 pediatric patients
T2 - A single institute's experience
AU - Yumura-Yagi, K.
AU - Inoue, M.
AU - Sakata, N.
AU - Okamura, T.
AU - Yasui, M.
AU - Sawada, A.
AU - Sato, E.
AU - Chayama, K.
AU - Endo, C.
AU - Sasabe, M.
AU - Miyamura, T.
AU - Park, Y. D.
AU - Nakano, T.
AU - Inagaki, J.
AU - Kishimoto, T.
AU - Nomura, K.
AU - Saito, I.
AU - Hamada, S.
AU - Nakano, T.
AU - Hashii, Y.
AU - Kawa, K.
PY - 2005/8
Y1 - 2005/8
N2 - In all, 100 unrelated donor bone marrow transplantations (UD-BMT) were performed in our institute between October 1993 and January 2003. Of 93 evaluable patients, 73 patients had hematological malignancy, 13 had nonmalignancy and seven had lymphoproliferative disease. The estimated 9-year event-free survival (EFS) rate was 57.1±5.5% in all patients. In the following analyses of the patients with hematological malignancy, the standard group had significantly better EFS than the high-risk group (61.5±7.0 vs 35.6±9.7%, P = 0.02), and the EFS rate of the tacrolimus (FK-506) + methotrexate (MTX)±methylprednisolone prophylactic group for graft-versus-host disease was superior to that of the FK-506 without MTX group (75.7±8.0 vs 55.8±7.6%, P = 0.02). When we compared the EFS rates of the FK506+MTX±methylprednisolone (mPSL) group and the HLA-matched related donor BMT group in our institute, these were almost similar (75.7±8.1 vs 68.4±9.3%). Therefore, UD-BMT using FK-506+MTX± mPSL is a safe and useful method for children with hematological malignancy who require allogeneic BMT.
AB - In all, 100 unrelated donor bone marrow transplantations (UD-BMT) were performed in our institute between October 1993 and January 2003. Of 93 evaluable patients, 73 patients had hematological malignancy, 13 had nonmalignancy and seven had lymphoproliferative disease. The estimated 9-year event-free survival (EFS) rate was 57.1±5.5% in all patients. In the following analyses of the patients with hematological malignancy, the standard group had significantly better EFS than the high-risk group (61.5±7.0 vs 35.6±9.7%, P = 0.02), and the EFS rate of the tacrolimus (FK-506) + methotrexate (MTX)±methylprednisolone prophylactic group for graft-versus-host disease was superior to that of the FK-506 without MTX group (75.7±8.0 vs 55.8±7.6%, P = 0.02). When we compared the EFS rates of the FK506+MTX±methylprednisolone (mPSL) group and the HLA-matched related donor BMT group in our institute, these were almost similar (75.7±8.1 vs 68.4±9.3%). Therefore, UD-BMT using FK-506+MTX± mPSL is a safe and useful method for children with hematological malignancy who require allogeneic BMT.
KW - Children
KW - Tacrolimus
KW - Unrelated bone marrow transplantation
UR - http://www.scopus.com/inward/record.url?scp=23944462929&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705056
DO - 10.1038/sj.bmt.1705056
M3 - 学術論文
C2 - 15968285
AN - SCOPUS:23944462929
SN - 0268-3369
VL - 36
SP - 307
EP - 313
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 4
ER -